Should I buy or sell Dianthus Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dianthus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNTH shares. View DNTH analyst ratings or view top-rated stocks .

What is Dianthus Therapeutics' stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Dianthus Therapeutics' shares. Their DNTH share price targets range from $23.00 to $45.00. On average, they predict the company's stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 183.7% from the stock's current price. View analysts price targets for DNTH or view top-rated stocks among Wall Street analysts .

How have DNTH shares performed in 2023?

Dianthus Therapeutics' stock was trading at $12.90 at the start of the year. Since then, DNTH shares have decreased by 16.2% and is now trading at $10.81. View the best growth stocks for 2023 here .

When is Dianthus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024. View our DNTH earnings forecast .

How were Dianthus Therapeutics' earnings last quarter?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($3.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $3.27. The firm had revenue of $0.92 million for the quarter, compared to analysts' expectations of $0.50 million.

Who are Dianthus Therapeutics' major shareholders?

Dianthus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (58.50%), Avidity Partners Management LP (32.13%), Atlas Venture Life Science Advisors LLC (6.25%), Laurion Capital Management LP (0.96%), Acadian Asset Management LLC (0.59%) and Citigroup Inc. (0.10%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa. View institutional ownership trends .

How do I buy shares of Dianthus Therapeutics?

Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Dianthus Therapeutics Stock Price, News & Analysis (NASDAQ:DNTH)

$10.84

-0.34 (-3.04%)

(As of 01:41 PM ET)

Compare

Today's Range: $10.58
▼
$11.36
50-Day Range: $11.18
▼
$13.67
52-Week Range: $5.14
▼
$26.24

Volume: 9,186 shs
Average Volume: 45,544 shs
Market Capitalization: $160.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $30.67

Dianthus Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 183.7% Upside
$30.67 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.69
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$1.31 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($8.91) to ($4.14) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

263rd out of 948 stocks

Pharmaceutical Preparations Industry

110th out of 448 stocks

3.5

Analyst's Opinion

Consensus Rating
Dianthus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $30.67, Dianthus Therapeutics has a forecasted upside of 183.7% from its current price of $10.81.
Amount of Analyst Coverage
Dianthus Therapeutics has only been the subject of 3 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for DNTH.

0.0

Dividend Strength

Dividend Yield
Dianthus Therapeutics does not currently pay a dividend.
Dividend Growth
Dianthus Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DNTH.

2.6

News and Social Media Coverage

News Sentiment
Dianthus Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Dianthus Therapeutics this week, compared to 1 article on an average week.
Search Interest
1 people have searched for DNTH on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Dianthus Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,314,676.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
11.56% of the stock of Dianthus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Dianthus Therapeutics are expected to grow in the coming year, from ($8.91) to ($4.14) per share.
Price to Book Value per Share Ratio
Dianthus Therapeutics has a P/B Ratio of 0.90. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

DNTH Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DNTH Stock News Headlines

November 29, 2023 | finance.yahoo.com

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

November 27, 2023 | americanbankingnews.com

Brokers Set Expectations for Dianthus Therapeutics, Inc.'s Q4 2023 Earnings (NASDAQ:DNTH)

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 25, 2023 | benzinga.com

Dianthus Therapeutics Stock (NASDAQ:DNTH), Analyst Ratings, Price Targets, Predictions

November 24, 2023 | benzinga.com

Dianthus Therapeutics Stock (NASDAQ:DNTH) Dividends: History, Yield and Dates

November 23, 2023 | americanbankingnews.com

Dianthus Therapeutics (NASDAQ:DNTH) Coverage Initiated by Analysts at Wedbush

November 22, 2023 | markets.businessinsider.com

Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst

November 22, 2023 | msn.com

Wedbush starts Dianthus at outperform, sees DNTH103 as well-positioned

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 22, 2023 | americanbankingnews.com

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 1%

November 18, 2023 | finance.yahoo.com

Dianthus Therapeutics, Inc. (DNTH)

November 9, 2023 | finance.yahoo.com

Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results

September 29, 2023 | benzinga.com

394K Reasons To Be Bullish On Dianthus Therapeutics Stock

September 24, 2023 | barrons.com

Dianthus Therapeutics Inc.

September 22, 2023 | benzinga.com

Dianthus Therapeutics Insider Trades Send a Signal

See More Headlines

Receive DNTH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/08/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DNTH
CUSIP: N/A
CIK: 1690585
Web: dianthustx.com
Phone: 857-242-0170
Fax: N/A
Employees: 32
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $30.67
High Stock Price Target: $45.00
Low Stock Price Target: $23.00
Potential Upside/Downside: +183.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-76,460,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -68.44%
Return on Assets: -59.60%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 14.64
Quick Ratio: 14.64

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.04 per share
Price / Book: 0.90

Miscellaneous

Outstanding Shares: 14,820,000
Free Float: 13,105,000
Market Cap: $160.20 million
Optionable: Not Optionable
Beta: 1.99

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Marino Garcia M.B.A. (Age 57)
President, CEO, Secretary & Director
Mr. Ryan Savitz
CFO & Treasurer
Mr. Edward G. Carr (Age 54)
Chief Accounting Officer
Mr. Judson Taylor
Head of Technical Operations
Dr. Susan Kalled Ph.D. (Age 61)
Chief Scientific Officer
Mr. Adam M. Veness Esq. (Age 37)
General Counsel
Ms. Kristina Maximenko
Chief People Officer
Mr. Simrat Randhawa M.B.A.
M.D., Chief Medical Officer
Ms. Rashieda Gluck
Head of Clinical Development Operations
Mr. Scott Nogi M.B.A.
Head of Business Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DNTH Stock Analysis - Frequently Asked Questions

Should I buy or sell Dianthus Therapeutics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dianthus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DNTH shares.
View DNTH analyst ratings or view top-rated stocks.
What is Dianthus Therapeutics' stock price target for 2024?: 3 Wall Street analysts have issued 1 year price objectives for Dianthus Therapeutics' shares. Their DNTH share price targets range from $23.00 to $45.00. On average, they predict the company's stock price to reach $30.67 in the next twelve months. This suggests a possible upside of 183.7% from the stock's current price.
View analysts price targets for DNTH or view top-rated stocks among Wall Street analysts.
How have DNTH shares performed in 2023?: Dianthus Therapeutics' stock was trading at $12.90 at the start of the year. Since then, DNTH shares have decreased by 16.2% and is now trading at $10.81.
View the best growth stocks for 2023 here.
When is Dianthus Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our DNTH earnings forecast.

How were Dianthus Therapeutics' earnings last quarter?: Dianthus Therapeutics, Inc. (NASDAQ:DNTH) issued its quarterly earnings data on Thursday, November, 9th. The company reported ($3.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $3.27. The firm had revenue of $0.92 million for the quarter, compared to analysts' expectations of $0.50 million.
Who are Dianthus Therapeutics' major shareholders?: Dianthus Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (58.50%), Avidity Partners Management LP (32.13%), Atlas Venture Life Science Advisors LLC (6.25%), Laurion Capital Management LP (0.96%), Acadian Asset Management LLC (0.59%) and Citigroup Inc. (0.10%). Insiders that own company stock include Fairmount Funds Management Llc and Simrat Randhawa.
View institutional ownership trends.
How do I buy shares of Dianthus Therapeutics?: Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:DNTH) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Dianthus Therapeutics Stock Price, News & Analysis (NASDAQ:DNTH)

Dianthus Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

Company Ownership

Earnings and Valuation

About Dianthus Therapeutics Stock (NASDAQ:DNTH)

DNTH Stock Price History

DNTH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

DNTH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™